BDX · ASX

BCAL Diagnostics Limited (ASX:BDX)

AU$0.071

 0.001 (1.429%)
ASX:Live
03/10/2025 04:10:29 PM
HALO Ords GROWTH AUS All-Consensus All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

BDX Overview

BDX Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Weak

GARP

Very Weak

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Weak

Earnings

Very Weak

Growth

Earnings

Very Weak

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

About BDX

Website

N/A

Telephone

N/A

Address

Description

BCAL Diagnostics Ltd. develops screening tests for the early detection of breast cancer. It also associated lipids, biomarker blood test that is used for prevention, screening and monitoring. The company was founded by Jayne Shaw and Ron Philips in 2010 and is headquartered in Sydney, Australia.

BDX Price Chart

Key Stats

Market Cap

AU$25.62M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.05 - 0.14

Trade Value (12mth)

AU$6,709.00

1 week

0%

1 month

11.11%

YTD

-29.29%

1 year

-50%

All time high

0.28

Key Fundamentals

EPS 3 yr Growth

21.10%

EBITDA Margin

%

Operating Cashflow

-$6m

Free Cash Flow Return

-74.50%

ROIC

-87.90%

Interest Coverage

-97.40

Quick Ratio

2.30

Other Data

Shares on Issue (Fully Dilluted)

366m

HALO Sector

Healthcare

Next Company Report Date

01-Sep-26

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

BDX Announcements

Latest Announcements

Date Announcements

24 September 25

Investor Update

×

Investor Update

23 September 25

Investor Webinar 24 September 2025 11am AEST

×

Investor Webinar 24 September 2025 11am AEST

18 September 25

BCAL and ClearNote Partner on Early Cancer Detection Tests

×

BCAL and ClearNote Partner on Early Cancer Detection Tests

08 September 25

Final Directors Interest Notice X 2

×

Final Directors Interest Notice X 2

08 September 25

Change of Director's Interest Notice

×

Change of Director's Interest Notice

29 August 25

Retirement of Non-Executive Directors

×

Retirement of Non-Executive Directors

29 August 25

Appendix 4E and Annual Report

×

Appendix 4E and Annual Report

29 August 25

Appendix 4G Corporate Governance Statement

×

Appendix 4G Corporate Governance Statement

27 August 25

BCAL Partners with Sonic Healthcare

×

BCAL Partners with Sonic Healthcare

30 July 25

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

03 July 25

Commercial Partnership with Cancer Care Associates

×

Commercial Partnership with Cancer Care Associates

06 May 25

BCAL Expands Access to Breastest Plus Sydney & Melbourne

×

BCAL Expands Access to Breastest Plus Sydney & Melbourne

28 April 25

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 March 25

BCAL to Host Analyst and Investor Webinar on 2 April 2025

×

BCAL to Host Analyst and Investor Webinar on 2 April 2025

24 March 25

BCAL Launches Breastest Plus Generating First Revenues

×

BCAL Launches Breastest Plus Generating First Revenues

24 March 25

Investor Presentation

×

Investor Presentation

28 February 25

Half Yearly Report and Accounts

×

Half Yearly Report and Accounts

31 January 25

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

19 December 24

Application for quotation of securities - BDX

×

Application for quotation of securities - BDX

19 December 24

Application for quotation of securities - BDX

×

Application for quotation of securities - BDX

19 December 24

Notification regarding unquoted securities - BDX

×

Notification regarding unquoted securities - BDX

19 December 24

Change of Directors Interest Notices X 6

×

Change of Directors Interest Notices X 6

19 December 24

Notification of cessation of securities - BDX

×

Notification of cessation of securities - BDX

19 December 24

Notification regarding unquoted securities - BDX

×

Notification regarding unquoted securities - BDX

19 December 24

Cleansing Notice

×

Cleansing Notice

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

BDX Shortsell

Frequently Asked Questions

The current share price of BCAL Diagnostics Limited (BDX:ASX) is AU$0.071.
The 52-week high share price for BCAL Diagnostics Limited (BDX:ASX) is AU$0.14.
The 52-week low share price for BCAL Diagnostics Limited (BDX:ASX)? is AU$0.05.
BCAL Diagnostics Limited (BDX:ASX) does not pay a dividend.
BCAL Diagnostics Limited (BDX:ASX) does not pay a dividend.
BCAL Diagnostics Limited (BDX:ASX) has a franking level of 0.0%.
BCAL Diagnostics Limited (BDX:ASX) is classified in the Healthcare.
The current P/E ratio for BCAL Diagnostics Limited (BDX:ASX) is .
The current share price of BCAL Diagnostics Limited (BDX:ASX) is AU$0.071.
The 52-week high share price for BCAL Diagnostics Limited (BDX:ASX) is AU$0.14.
The 52-week low share price for BCAL Diagnostics Limited (BDX:ASX)? is AU$0.05.
BCAL Diagnostics Limited (BDX:ASX) does not pay a dividend.
BCAL Diagnostics Limited (BDX:ASX) does not pay a dividend.
BCAL Diagnostics Limited (BDX:ASX) has a franking level of 0.0%.
BCAL Diagnostics Limited (BDX:ASX) is classified in the Healthcare.
The current P/E ratio for BCAL Diagnostics Limited (BDX:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox
App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.

Ff